Does Immunohistochemistry Provide Additional Prognostic Data in Gastrointestinal Stromal Tumors?

被引:12
作者
Demir, Lutfiye [1 ]
Ekinci, Nese [2 ]
Erten, Cigdem [1 ]
Kucukzeybek, Yuksel [1 ]
Alacacioglu, Ahmet [1 ]
Somali, Isil [3 ]
Can, Alper [1 ]
Dirican, Ahmet [1 ]
Bayoglu, Vedat [1 ]
Akyol, Murat [1 ]
Cakalagaoglu, Fulya [2 ]
Tarhan, Mustafa Oktay [1 ]
机构
[1] Izmir Katip Celebi Univ, Ataturk Training & Res Hosp, Dept Med Oncol, Izmir, Turkey
[2] Izmir Katip Celebi Univ, Ataturk Training & Res Hosp, Dept Pathol, Izmir, Turkey
[3] Dokuz Eylul Univ, Inst Oncol, Dept Med Oncol, TR-35210 Alsancak, Turkey
关键词
Gastrointestinal stromal tumor; immunohistochemistry; predictive potential; prognosis; IMATINIB MESYLATE; C-KIT; GIST; MUTATIONS; SURVIVAL; RECURRENCE; RESISTANCE; DIAGNOSIS;
D O I
10.7314/APJCP.2013.14.8.4751
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: To investigate the predictive and prognostic effects of clinicopathologic and immunohistochemical (IHC) features in patients with gastrointestinal stromal tumours (GISTs). Materials and Methods: Fifty-six patients who were diagnosed with GIST between 2002 and 2012 were retrospectively evaluated. Relationships between clinicopathologic/immunohistochemical factors and prognosis were investigated. Results: Median overall survival (OS) of the whole study group was 74.9 months (42.8-107.1 months), while it was 95.2 months in resectable and 44.7 months in metastatic patients respectively (p=0.007). Epitheliolid tumor morphology was significantly associated with shortened OS as compared to other histologies (p=0.001). SMA(+) tumours were significantly correlated with low (<10/50HPF) mitotic activity (p=0.034). Moreover, SMA(+) patients tended to survive longer and had significantly longer disease-free survival (DFS) times than SMA (-) patients (37.7 months vs 15.9 months; p=0.002). High Ki-67 level (>= 30%) was significantly associated with shorter OS (34 vs 95.2 months; 95% CI; p=0.001). CD34 (-) tumours were significantly associated with low proliferative tumours (Ki-67<% 10) (p=0.026). Median PFS (progression-free survival) of the patients who received imatinib was 36 months (27.7-44.2 months). CD34 (-) patients had significantly longer PFS times than that of negative tumours; (50.8 vs 29.8 months; p=0.045). S100 and desmin expression did not play any role in predicting the prognosis of GISTs. Multivariate analysis demonstrated that >= 10/50HPF mitotic activity/HPF was the only independent factor for risk of death in GIST patients. Conclusions: Despite the negative prognostic and predictive effect of high Ki-67 and CD34 expression, mitotic activity remains the strongest prognostic factor in GIST patients. SMA positivity seems to affect GIST prognosis positively. However, large-scale, multicenter studies are required to provide supportive data for these findings.
引用
收藏
页码:4751 / 4758
页数:8
相关论文
共 44 条
[21]   Gastrointestinal stromal tumors in Koreans: It's incidence and the clinical, pathologic and immunohistochemical findings [J].
Kim, KM ;
Kang, DW ;
Moon, WS ;
Park, JB ;
Park, CK ;
Sohn, JH ;
Jeong, JS ;
Cho, MY ;
Jin, SY ;
Choi, JS ;
Kang, DY .
JOURNAL OF KOREAN MEDICAL SCIENCE, 2005, 20 (06) :977-984
[22]  
Kindblom LG, 1998, AM J PATHOL, V152, P1259
[23]   Gastrointestinal stromal tumours (GISTs): a clinicopathological and molecular study of 66 cases [J].
Koay, MHE ;
Goh, YW ;
Iacopetta, B ;
Grieu, F ;
Segal, A ;
Sterrett, GF ;
Platten, M ;
Spagnolo, DV .
PATHOLOGY, 2005, 37 (01) :22-31
[24]   The Lack of CD34 Expression in Gastrointestinal Stromal Tumors is Related to Cystic Degeneration Following Imatinib Use [J].
Koh, Youngil ;
Lee, Hee Eun ;
Oh, Do-Youn ;
Kim, Jee Hyun ;
Lee, Se-Hoon ;
Kim, Se Hyung ;
Kim, Dong-Wan ;
Im, Seock-Ah ;
Kim, Tae-You ;
Heo, Dae Seog ;
Kim, Woo-Ho ;
Bang, Yung-Jue .
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2012, 42 (11) :1020-1027
[25]   Post-operative imatinib in patients with intermediate or high risk gastrointestinal stromal tumor [J].
Li, J. ;
Gong, J. F. ;
Wu, A. W. ;
Shen, L. .
EJSO, 2011, 37 (04) :319-324
[26]  
Liang Yu-mei, 2008, Zhonghua Yi Xue Za Zhi, V88, P1041
[27]   Deletions affecting codons 557-558 of the c-KIT gene indicate a poor prognosis in patients with completely resected gastrointestinal stromal tumors:: A study by the Spanish Group for Sarcoma Research (GEIS) [J].
Martín, J ;
Poveda, A ;
Llombart-Bosch, A ;
Ramos, R ;
López-Guerrero, JA ;
del Muro, JG ;
Maurel, J ;
Calabuig, S ;
Gutierrez, A ;
de Sande, JLG ;
Martínez, J ;
De Juan, A ;
Laínez, N ;
Losa, F ;
Alija, V ;
Escudero, P ;
Casado, A ;
García, P ;
Blanco, R ;
Buesa, JM .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (25) :6190-6198
[28]  
Mazurenko NN, 2011, ASCP GI CANC S S4, V29, P49
[29]   Gastrointestinal stromal tumors - definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis [J].
Miettinen, M ;
Lasota, J .
VIRCHOWS ARCHIV, 2001, 438 (01) :1-12
[30]   Gastrointestinal stromal tumors of the jejunum and ileum - A clinicopathologic, immunohistochemical, and molecular genetic study of 906 cases before imatinib with long-term follow-up [J].
Miettinen, M ;
Makhlouf, H ;
Sobin, LH ;
Lasota, J .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2006, 30 (04) :477-489